| Biomarker ID | 429 |
| PMID | 19239456 |
| Year | 2009 |
| Biomarker | p53 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased Expression with Overall Death |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 1.87 (95% CI: 1.30-2.68); Multivariate: HR: 1.73 (95% CI: 1.19-2.51) |
| Effect on Pathways | Pathways Include:- Apoptosis intrinsic pathway, Thyroid cancer,BARD1 signaling events,Fluoropyrimidine activity,Tumor suppressor Arf inhibits ribosomal biogenesis |
| Experiment | Overall Survival Vs No Survival |
| Type of Biomarker | Prognostic |
| Cohort | The analysis included 1844 cancerous cores from 705 eligible patients with clinically localized prostate cancer, who were treated conservatively. The analysis included subcohort from the original 705 patients with Gleason score >7. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: p=0.001; Multivariate: p=0.004; |
| Method Used | immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TP53 |